共查询到19条相似文献，搜索用时 250 毫秒
1.
应用荷兰农业部提供的鸡马立克氏病（ＭＤ）ＣＶＩ９８８／Ｒｉｓｐｅｎｓ Ⅰ型致弱种毒, 在农业部批准的符合ＧＭＰ 要求的生产车间研制出鸡马立克氏病ＣＶＩ９８８／Ｒｉｓｐｅｎｓ 疫苗。将按国际标准检验合格的三批疫苗及进口商品ＣＶＩ９８８／Ｒｉｓｐｅｎｓ 疫苗接种１ 日龄ＳＰＦ 雏鸡, 于７ 日龄经腹腔攻击鸡马立克氏病强毒（北京－ １ 株） 血毒, 全部鸡只隔离饲养观察至６０ 日龄并作全群剖检。经测定： 非免疫攻毒组１００％ 发病,健康对照组全部阴性, 三批国产ＣＶＩ９８８／Ｒｉｓｐｅｎｓ 疫苗保护指数分别为９０－０, ９０－０, ９３－３ , 进口商品苗保护率为９３－３ 。结果表明国产和进口ＣＶＩ９８８／Ｒｉｓｐｅｎｓ疫苗均能提供对ＭＤ 较高的免疫保护力, 国产疫苗的保护效果达到了国际同类产品的先进水平。 相似文献
2.
北京市农林科学院畜牧兽医研究所，经中华人民共和国动植物检疫局批准，引进ＣＶＩ９８８／Ｒｉｓｐｅｎｓ制苗毒株，按国际规定质量标准，使用ＳＰＦ（无特定病原）鸡胚，应用细胞培养法制造出ＣＶＩ９８８鸡马立克氏病１型细胞结合性液氮苗。ＣＶＩ９８８活疫苗的免疫性高，能抵抗鸡马立克氏病超强毒，免疫后５日龄即可产生坚强免疫力，疫苗每羽份独斑单位达４０００～６０００。该疫苗具有同源性，不受母源抗体的干扰，预防减少率比冻干苗高２０％以上，可达９０％－９５％，质量达到国际同类产品水平，而且价格也适合中国现有国情。该疫… 相似文献
3.
用表达马立克氏病病毒（ＭＤＶ（Ｉ型疫苗株ＣＶ１９８８／Ｒｉｓｐｅｎｓ糖蛋白Ｂ（ｇＢ）基因的重组鸡痘病毒（ｒＦ－ＰＶ－ｇＢ／Ｒ）和鸡痘病毒（ＦＰＶ）疫苗株２８２Ｅ４免疫１日龄不同品种的鸡,来评价２种病毒株的安全性及免疫母源抗体的商品是我毒性,而对无毒源抗体的ＳＰＦ鸡的毒性则不同。斑点杂交和Ｓｏｕｔｈｅｒｎ杂交产,ｆＦＰＶ－ｇＢ／Ｒ中无氨苄青霉素的抗性基因。 相似文献
4.
应用宜兴赛尔生物化工厂产１９９、Ｆ－１０、１６４０和ＤＭＥＭ细胞培养基与美国Ｓｉｇｍａ公司产１９９、Ｆ－１０、１６４０和ＤＭＥＭ细胞培养基分别配制细胞培养液，培养ＳＰ２／０和Ｖｅｒｏ细胞系及原代鸡胚成纤维细胞（ＣＥＦ），做细胞培养动力学比较试验。比较这两种来源的细胞培养基对细胞生长的形态、分裂速度及鸡马立克氏病毒（Ｍａｒｅｋ＇ｓｄｉｓｅａｓｅｖｉｒｕｓ．ＭＤＶ）疫苗毒株ＨＶＴ－ＦＣ１２６和ＲｉｓｐｅｎｓＣＶＩ９８８在ＣＥＦ单层上增殖量的差异。研究结果表明，四种国产细胞培养基与对应的四种进口培养基对细胞生长及病毒增殖的影响无显著差异 相似文献
5.
ＭＤＶＣＶＩ９８８株是由Ｒｉｓｐｅｎｓ等人（１９７２）采用原代鸭胚成纤维细胞（ＤＥＦ）健康白色来航鸡中分离得到的,其第３５代细胞培养毒是目前荷兰使用最为广泛的ＭＤ疫苗。１９８３年荷兰约有４７６０多万只蛋鸡接种过该疫苗;约有９７０万只蛋鸡接种了火鸡疤疹病毒（ＨＶＴ）Ｆｃ１２６疫苗。这段时间因ＭＤ造成的损失相对较低,死亡率不超过２．５％。在特定条件下（通常是环境卫生较好的农场）,ＭＤＶＣＶＩ９８８疫苗第３５代细胞培养物传代病毒能表现出令人满意的保护效力,对生产鸡只也很安全。关于ＭＤ疫苗,特别是ＣＶＩ… 相似文献
6.
一、疫苗生产及质量标准关于疫苗的生产质量问题，最重要的是对疫苗本身的免疫效力、安全性和外源病原污染等方面的了解。其决定因素是应认真考虑生产疫苗的毒种是否来源正规，符合标准，以及制苗种毒和疫苗代次的确定是否合理，疫苗效价是否保证等。１．制苗种毒的来源：在中国，１９９８年首次由北京市农林科学院畜牧兽医研究所独家从荷兰引进该制苗种毒并进行了产业化生产ＣＶＩ９８８／Ｒｉｓｐｅｎｓ冷冻疫苗。由于该疫苗在国内的大量推广及有良好应用前景，因此，目前一些单位或个人试图通过各种途径从其他国家获得该毒种，但如果这些… 相似文献
7.
鸡传染性法氏囊病毒血清Ⅰ型和亚型混合弱毒疫苗研究初报 总被引：2，自引：0，他引：2
由美国ＩＢＤ血清Ⅰ型商品弱毒疫苗Ｂｕｒｓａ－Ｖａｃ，Ｕｎｉｖａｘ ＢＤ和中国广东的亚型弱毒疫苗ＣＮ９０３，ＣＳ９０４混合组成的弱毒疫苗，免疫剂量为１０００ＴＣＩＤ５０，对１２日龄无ＩＢＤ血清中和抗体或≤１：８的试验鸡，免疫试验结果表明，免疫后７天，能够产生９０－１００％的保护作用。ＩＢＤ混和弱毒疫苗保存在３４－３７℃１周，４－１０℃４周和－２５℃１２个月，疫苗的免疫保护率仍达１００％。对５个品种的 相似文献
8.
用同胚培养的含ＮＤＶ、ＩＢＶ胚液制备的二联油乳剂灭活苗，经免疫效力试验表明，用５０倍稀释的鸡二联灭活苗，０．５ｍｌ／只剂量免疫１８日龄鸡，４周后试验免疫鸡分别进行ＮＤＶ、ＩＢＶ强毒攻击，攻毒保护率在５０％以上，证明０．５ｍｌ剂量含有５０个半数保护量（５０个ＰＤ５０），ＮＤＨＩ抗体≥１：１６，ＩＢＶＮ抗体≥１：８便可保护。三批疫苗免疫１８日龄鸡，０．５ｍｌ／只组免疫鸡体现人有效抗体可维持１６周以上， 相似文献
9.
马兴树 《中国预防兽医学报》1994,(2)
鸡传染性法氏囊病（ＩＢＤ）Ｖｅｒｏ细胞弱毒疫苗（ＶＣＶ９０１）病毒滴度为１０￣（７．３）～１０￣（８．３）ＴＣＩＤ＿（５０）／０．０５ｍｌ．疫苗经皮下、肌内、点眼－滴鼻和口服途径免疫接种雏鸡，均表现出良好的免疫原性。皮下接种１４日龄雏鸡，免疫后８、１４和２１天攻毒，保护数分别为２／６、６／６５／６，如在３５日龄再加强免疫一次，于二免后７０天和１１５天攻毒．其保护数分别为６／６和５／６．疫苗的最小免疫剂量为１０￣５ＴＣＩＤ＿（５０）／只，用１０、５０和１００培免疫剂量免疫雏鸡，临床表现均安全，不影响雏鸡增重．经易感雏鸡连传５代，疫苗毒力不返强．温苗在－２０℃～－２５℃至少保存一年，在０℃可保存一周，疫苗对鸡无致瘤性． 相似文献
10.
１日龄健康ＡＡ雏鸡感染ＣＩＡＶ后８天进行ＮＤ疫苗免疫，免疫后２９天用ｖＮＤＶ攻击，于免疫后７、１４、２８和攻毒后１０天取材检测．给果，感染ＣＩＡＶ雏鸡经ＮＤ免疫后７天，胸腺Ｔ细胞白细胞介素２（ＩＬ－２）诱生活性比未感染的免疫对照鸡明显降低（Ｐ＜０．０１）；脾脏Ｔ细胞ＩＬ－２诱生活性于７和２８天显著降低（Ｐ＜０．０５，Ｐ＜０．０１）．感染免疫鸡免疫后１４天脾脏淋巴细胞干扰素（ＩＦＮ）诱生活性明显降低（Ｐ＜０．０１）．结果表明感染ＣＩＡＶ鸡对ＮＤ疫苗免疫的分子免疫调节作用明显减弱，ＨＩ抗体效价于免疫后７～２８日明显降低（Ｐ＜０．０５）。ＮＤ强毒攻击后，ＣＩＡＶ感染ＮＤ免疫雏鸡的免疫保护率为６０％％，明显低于免疫对照鸡（１００％）． 相似文献
11.
Earlier studies have shown that the B haplotype has a significant influence on the protective efficacy of vaccines against Marek's disease (MD) and that the level of protection varies dependent on the serotype of MD virus (MDV) used in the vaccine. To determine if the protective glycoprotein gene gB is a basis for this association, we compared recombinant fowlpox virus (rFPV) containing a single gB gene from three serotypes of MDV. The rFPV were used to vaccinate 15.B congenic lines. Nonvaccinated chickens from all three haplotypes had 84%-97% MD after challenge. The rFPV containing gB1 provides better protection than rFPV containing gB2 or gB3 in all three B genotypes. Moreover, the gB proteins were critical, since the B*21/*21 chickens had better protection than chickens with B*13/*13 or B*5/*5 using rFPV with gB1, gB2, or gB3. A newly described combined rFPV/gB1gEgIUL32 + HVT vaccine was analyzed in chickens of lines 15 x 7 (B*2/*15) and N (B*21/*21) challenged with two vv+ strains of MDV. There were line differences in protection by the vaccines and line N had better protection with the rFPV/gB1gEgIUL32 + HVT vaccines (92%-100%) following either MDV challenge, but protection was significantly lower in 15 X 7 chickens (35%) when compared with the vaccine CVI988/Rispens (94%) and 301B1 + HVT (65%). Another experiment used four lines of chickens receiving the new rFPV + HVT vaccine or CVI988/Rispens and challenge with 648A MDV. The CVI 988/Rispens generally provided better protection in lines P and 15 X 7 and in one replicate with line TK. The combined rFPV/gB1gEgIUL32 + HVT vaccines protected line N chickens (90%) better than did CVI988/Rispens (73%). These data indicate that rFPV + HVT vaccines may provide protection against MD that is equivalent to or superior to CVI988/ Rispens in some chicken strains. It is not clear whether the rFPV/gB1gEgIUL32 + HVT vaccine will offer high levels of protection to commercial strains, but this vaccine, when used in line N chickens, may be a useful model to study interactions between vaccines and chicken genotypes and may thereby improve future MD vaccines. 相似文献
12.
Marek's disease (MD) is a lymphoproliferative disease of domestic chickens caused by a highly infectious, oncogenic alpha-herpesvirus known as Marek's disease virus (MDV). MD is presently controlled by vaccination. Current MD vaccines include attenuated serotype 1 strains (e.g., CVI988/Rispens), avirulent serotype 2 (SB-1), and serotype 3 (HVT) MDV strains. In addition, recombinant MDV strains have been developed as potential new and more efficient vaccines to sustain the success of MD control in poultry. One of the candidate recombinant MDV strains, named rMd5deltaMeq, was derived from Md5, a very virulent strain of MDV lacking the MDV oncogene Meq. Our earlier reports suggest that rMd5deltaMeq provided protection equally well or better than commonly used MD vaccines in experimental and commercial lines of chickens challenged with very virulent plus (vv+) strains of MDV. In this study, maternal antibody-positive (trial 1) and negative (trial 2) chickens from a series of relatively MD resistant lines were either vaccinated with the rMd5deltaMeq or CVI988/Rispens followed by infection of a vv+ strain of MDV, 648A, passage 10. This report presents experimental evidence that the rMd5deltaMeq protected significantly better than the CVI988/Rispens (P < 0.01) in the relatively resistant experimental lines of chickens challenged with the vv+ strain of MDV. Together with early reports, the rMd5deltaMeq appeared to provide better protection, comparing with the most efficacious commercially available vaccine, CVI988/Rispens, for control of MD in lines of chickens regardless of their genetic background. 相似文献
13.
Objective To develop a serotype 1 Marek's disease (MD) vaccine from a very virulent MDV (vvMDV) pathotype and demonstrate safety and efficacy against early challenge with very virulent field strains in the presence of maternal antibody.
Study design Strain BH 16 was isolated and attenuated by serial cell culture passage. One of two cloned passages was selected for vaccine development following early laboratory-scale protection trials in commercial birds. Comparative protection trials were carried out on the BH 16 vaccine and on a CVI 988 Rispens vaccine using commercial and SPF chickens. Challenge viruses used were either a low passage strain BH 16 virus, the Woodlands No. 1 strain or MPF 57 strain of MDV. The BH 16 vaccine was back-passaged in SPF chickens six times and virus recovered from the final passage and the original vaccine virus were tested for safety. The immunosuppressive potential of the BH 16 and Rispens vaccines was also assessed in parallel.
Results The BH 16 and Rispens vaccines induced comparable levels of protection when used as monovalent or multi-valent vaccines, although protection achieved with the mono-valent vaccines was lower. No gross tumour formation was evident in any birds receiving the BH 16 vaccine or bird-passaged virus, although microscopic lesions were present in 2/12 birds that received the bird-passaged virus. In tests for immunosuppression, there was no histological evidence of damage to either the bursa of Fabricius or the thymus.
Conclusion The BH 16 vaccine was shown to be safe and at least as protective as the Rispens vaccine against three highly virulent MD challenge viruses. 相似文献
Study design Strain BH 16 was isolated and attenuated by serial cell culture passage. One of two cloned passages was selected for vaccine development following early laboratory-scale protection trials in commercial birds. Comparative protection trials were carried out on the BH 16 vaccine and on a CVI 988 Rispens vaccine using commercial and SPF chickens. Challenge viruses used were either a low passage strain BH 16 virus, the Woodlands No. 1 strain or MPF 57 strain of MDV. The BH 16 vaccine was back-passaged in SPF chickens six times and virus recovered from the final passage and the original vaccine virus were tested for safety. The immunosuppressive potential of the BH 16 and Rispens vaccines was also assessed in parallel.
Results The BH 16 and Rispens vaccines induced comparable levels of protection when used as monovalent or multi-valent vaccines, although protection achieved with the mono-valent vaccines was lower. No gross tumour formation was evident in any birds receiving the BH 16 vaccine or bird-passaged virus, although microscopic lesions were present in 2/12 birds that received the bird-passaged virus. In tests for immunosuppression, there was no histological evidence of damage to either the bursa of Fabricius or the thymus.
Conclusion The BH 16 vaccine was shown to be safe and at least as protective as the Rispens vaccine against three highly virulent MD challenge viruses. 相似文献
14.
Derivation,safety and efficacy of a Marek's disease vaccine developed from an Australian isolate of very virulent Marek's disease virus 总被引：4，自引：0，他引：4
OBJECTIVE: To develop a serotype 1 Marek's disease (MD) vaccine from a very virulent MDV (vvMDV) pathotype and demonstrate safety and efficacy against early challenge with very virulent field strains in the presence of maternal antibody. STUDY DESIGN: Strain BH 16 was isolated and attenuated by serial cell culture passage. One of two cloned passages was selected for vaccine development following early laboratory-scale protection trials in commercial birds. Comparative protection trials were carded out on the BH 16 vaccine and on a CVI 988 Rispens vaccine using commercial and SPF chickens. Challenge viruses used were either a low passage strain BH 16 virus, the Woodlands No. 1 strain or MPF 57 strain of MDV. The BH 16 vaccine was back-passaged in SPF chickens six times and virus recovered from the final passage and the original vaccine virus were tested for safety. The immunosuppressive potential of the BH 16 and Rispens vaccines was also assessed in parallel. RESULTS: The BH 16 and Rispens vaccines induced comparable levels of protection when used as monovalent or multivalent vaccines, although protection achieved with the monovalent vaccines was lower. No gross tumour formation was evident in any birds receiving the BH 16 vaccine or bird-passaged virus, although microscopic lesions were present in 2/12 birds that received the bird-passaged virus. In tests for immunosuppression, there was no histological evidence of damage to either the bursa of Fabricius or the thymus. CONCLUSION: The BH 16 vaccine was shown to be safe and at least as protective as the Rispens vaccine against three highly virulent MD challenge viruses. 相似文献
15.
OBJECTIVE: To demonstrate the safety and efficacy of the Marek's Disease Virus-1 vaccine (strain BH 16) from field studies in comparison with the CVI 988 Rispens vaccine currently available in Australia. STUDY DESIGN: A small field trial was carried out on nine breeder flocks and a larger trial on 21 breeder flocks. All chickens were obtained from a commercial hatchery and each was vaccinated at hatch with cell-associated Herpes Virus of Turkeys vaccine. A group of chickens vaccinated with BH 16 vaccine was placed in one shed per property and the remainder were vaccinated with the Rispens vaccine and placed in the remaining sheds. At 25, 30, 35, and 40 weeks after hatch, the field veterinarian or farm manager examined all birds dying on two consecutive days in the designated placement sheds. RESULTS: In the small trial there was a significantly lower incidence of MD in birds vaccinated with the MDV-1 vaccine compared with the Rispens vaccine (P < 0.001). In a larger trial there was no difference in the incidence of MD between the treatment groups, due possibly to a lower rate of natural challenge. Egg production results and average weekly mortality results for both groups were similar. CONCLUSION: The present study describes an attenuated type 1 MD vaccine which is at least equivalent to a vaccine derived from the CVI 988 Rispens strain in terms of safety and efficacy when used in combination with HVT vaccine. 相似文献
16.
鸡马立克氏病活疫苗免疫效力比较试验 总被引：1，自引：0，他引：1
用ＨＶＴ冻干苗、ＨＶＴ细胞结合苗、ＣＶＩ９８８细胞结合苗、ＳＢ１＋ＦＣ１２６双价活疫苗、３０１Ｂ／１＋ＦＣ１２６双价活疫苗和Ｚ４＋ＦＣ１２６双价活疫苗等６种鸡马立克氏病（ＭＤ）疫苗免疫ＳＰＦ白来航鸡或普通伊莎鸡，用鸡马立克氏病病毒（ＭＤＶ）强毒ＧＡ株、京－１血毒以及鸡马立克氏病超强毒ｖｖＭＤＶ－Ｍｄ５毒株分别攻击进行免疫效力比较试验。试验表明，ＭＤ单价苗的免疫效力强弱顺序依次是ＣＶＩ９８８、ＨＶＴ细胞结合苗和ＨＶＴ冻干苗，这３种ＭＤ单价苗均能给免疫鸡群提供有效的免疫保护力。ＳＢ１＋ＦＣ１２６、Ｚ４＋ＦＣ１２６和３０１Ｂ／１＋ＦＣ１２６等３种ＭＤ双价苗免疫效力显著高于ＭＤ单价苗，均能给免疫鸡群提供较强的免疫保护力，并能有效地抵抗ｖｖＭＤＶ－Ｍｄ５毒株的致瘤作用。Ｚ４＋ＦＣ１２６和３０１Ｂ／１＋ＦＣ１２６ＭＤ双价苗免疫效力无显著差异 相似文献
17.
meq是鸡马立克病病毒（MDV）最重要的致瘤基因，在马立克病（MD）肿瘤发生中发挥关键作用。同时，它在疫苗株和强毒株之间具有明显的序列差异性。本文利用CRISPR/Cas9基因编辑技术，以MDV疫苗株CVI988/Rispens meq基因为靶点，设计合成gRNA，克隆构建pX459-gRNA质粒，转染CEF并感染CVI988/Rispens，然后对meq基因编辑的病毒噬斑进行克隆纯化，经过PCR扩增、测序分析及IFA鉴定，成功构建1株meq基因编辑的缺失毒株CVI988Δmeq-C7，为后续筛选和鉴定抗MD疫苗株MEQ单抗及鉴别诊断研究奠定了基础。 相似文献
18.
Improved vaccines to control Marek's disease (MD) in chickens are desired by the poultry industry but have been difficult to develop. Studies were conducted to evaluate strategies for deriving MD vaccines of high protective efficacy, irrespective of virulence. Candidate viruses from parent strains representing v and vv+ pathotypes were modified by cell culture passage, backpassage in chickens, or insertional mutagenesis following cocultivation with retroviruses. Ten strains considered most likely to exhibit high protective efficacy were selected for further study. The ability of these modified viruses to protect commercial or maternal antibody-positive (ab+) chickens against virulent MD virus (MDV) challenge was compared with that of strain CVI988, the standard commercial MD vaccine. Modified strains were also evaluated for the ability to induce lymphomas or other pathologic changes in ab+ and antibody-negative (ab-) chickens. Two of the 10 modified viruses, strains RM1 and CVI988/BP5, provided high levels of protection against highly virulent MDV challenge. The magnitude of protection was greater than that of one laboratory and two commercial preparations of CV1988, but was approximately equal to that of two other commercial preparations of CVI988 in laboratory and field tests. Three of the strains, including RMI and CVI988/BP5, induced lymphoid organ atrophy in ab-chicks but not in ab+ commercial chicks, a property designated here as L phenotype. Seven strains, including two L+ strains, were mildly oncogenic for ab- chicks, a property designated here as O phenotype. Five of these strains caused no tumors in ab+ chickens. The two fully attenuated strains induced neither lymphomas nor lymphoid organ atrophy. The L and O phenotypes appeared not to be linked, and both (especially the L phenotype) appeared associated with high levels of protection. These studies also illustrated differences in the protective efficacy of different preparations of CVI988 vaccine, indicating the need to choose carefully the most protective strains as controls for efficacy studies. A new vv+ strain, designated as 686, is described and appears useful as a challenge virus; it is the most virulent of the 48 field isolates of MDV thus far pathotyped in this laboratory. These findings support the conclusion that new virus strains with high levels of protective immunity comparable to that of CVI988 can be developed. However, the question of whether strains can be developed that exceed the efficacy of current CVI988-based vaccines remains unanswered. After more than 30 years of unsuccessful endeavor by many laboratories toward this goal, it now may be useful to consider whether the efficacy of MD vaccines is limited by some type of biologic threshold. 相似文献
19.
S.J. Baigent L.P. Smith L.J. Petherbridge V.K. Nair 《Research in veterinary science》2011,91(1):167-174
The ‘gold standard’ vaccine against Marek’s disease in poultry is the CVI988/Rispens virus, which is not easily distinguishable, antigenically or genetically, from virulent Marek’s disease herpesvirus. Accurate differential measurement of the CVI988 vaccine and virulent viruses is important to investigate mechanisms of vaccinal protection. Minimal sequence differences between CVI988 and virulent MDV strains restrict the application of molecular diagnostic methods such as real-time PCR to distinguish between these viruses. The use of bacterial-artificial-chromosome (BAC) cloned CVI988 virus, which carries the BAC vector sequences in place of the Us2 gene, allows its differential quantification from virulent strains using real-time PCR assays that target the BAC vector sequence and the US2 gene respectively. These novel assays allowed investigation of replication of both serotype-1 vaccine virus (cloned CVI988) and challenge virus (RB-1B strain) in tissues of individual chickens in an experimental vaccination-challenge model of Marek’s disease. 相似文献